Integrated Leadership in Drug Discovery, Development & Biotech Growth

A seasoned entrepreneur and technology leader who founded and led a technology transfer company that successfully spun off six ventures, all led by Kent Murphy and later acquired by major corporations. Led the parent company to consistent profitability and growth from inception through its NASDAQ IPO fifteen years later, accomplished entirely without outside funding. Led the financing of spinouts through a combination of angel investors, venture capital, corporate partners, private equity, family offices, and public funds.

Developed dozens of industry-defining products across surgical robotics, oil and gas instrumentation, wireless and satellite communications, space-qualified smart materials, and advanced sensing systems. Technologies under Dr. Murphy's leadership were acquired by Intuitive Surgical, Baker Hughes, IHS Markit, Bio-Rad, and several defense contractors, generating substantial returns and supporting over 700 high-tech jobs in Southwest Virginia.

In 2015, left the first group of companies to found new ventures in women's health diagnostics and RaCRx Bio, both funded to date by small angel network. Recognized for the ability to identify unmet market needs, align technology innovation with commercial opportunity, and build high-performance teams from concept through commercialization. Licensed and advanced the immunomodulatory compound β-alethine toward clinical development and established licensing and research collaborations with universities, federal laboratories, and industrial partners including Bell Labs.

Holds over 40 issued patents across telecommunications, sensing, and biotechnology, collectively contributing to billions of dollars in revenue and corporate value creation.

Internist, Medical Oncologist, and translational scientist with over 40 years of discovery-to-market impact across cancer and metabolic disease (diabetes, obesity) diagnostics and targeted therapeutics. Discoverer of multiple oncogenes during a 30-year academic medicine career, including ALK, BCL10, NPM-MLF1, and RBM15-MKL1, enabling the creation of five FDA-approved ALK inhibitors (XALKORI®, ALECENSA®, ALUNBRIG®, LORBRENA®, ZYKADIA®) and other targeted agents in development.

Founder of diagnostics assay developer Insight Genetics (acquired by Insight Molecular Diagnostics, Nasdaq: IMDX), where pioneering work led to globally marketed assays such as the FDA-cleared ALK FISH companion diagnostic.

Published 165+ high-impact articles (Nature, Science, Cell, Cancer Discovery, Journal of Medicinal Chemistry, etc.) and holds multiple patents in cancer biology and diagnostics. Currently advises and leads development strategy as CDO/CMO for innovative oncology and metabolic disease biotech companies such as Biomea Fusion (BMEA) and others, translating cutting-edge research into precision medicines and diagnostics that expand patient access to breakthrough therapies.

Strategic R&D leader with 20+ years of experience advancing small-molecule therapies from discovery to market, including contributions to risdiplam (Evrysdi®), the first oral spinal muscular atrophy (SMA) therapy. Guided neuroscience programs from target identification through lead optimization at PTC Therapeutics (Nasdaq: PTCT) and currently advise the Foundation for Angelman Syndrome Therapeutics (FAST) on the therapeutic strategy for Angelman syndrome.

Deep expertise across neurology, muscular dystrophies, oncology, and genetic disorders, built on postdoctoral training at The Johns Hopkins School of Medicine and supported by 25+ peer-reviewed publications. Skilled in early drug discovery, translational strategy, and cross-functional program leadership, with a proven ability to build teams, shape research strategy, and translate innovation into therapeutic advancement.

Professor at the University of North Carolina at Chapel Hill and Chief Scientific Officer of RaCRx Fusion, bringing deep expertise in computational biology, machine learning, and AI-driven approaches to drug discovery and development. Dr. Wang's academic research bridges quantitative modeling and translational science, applying advanced computational methods to accelerate the identification and optimization of novel therapeutic candidates.

Her work spans multi-omics data integration, predictive biomarker development, and the application of artificial intelligence to complex biological systems — capabilities that directly underpin RaCRx Fusion's platform for data-driven precision medicine. Dr. Wang's dual role as an active research professor and industry CSO ensures that RaCRx Fusion's computational engine remains at the frontier of academic innovation while maintaining rigorous translational focus.

Professor at the University of North Carolina at Chapel Hill and Chief Technology Officer of RaCRx Fusion, with deep expertise in cancer biology, signal transduction, and the molecular mechanisms underlying tumor development and progression. Dr. Liu's laboratory focuses on understanding how oncogenic signaling pathways drive cancer cell growth and survival, with a translational emphasis on converting mechanistic insights into actionable therapeutic strategies.

His research has produced high-impact findings in the regulation of key oncoproteins and tumor suppressors, informing the development of next-generation targeted therapies. As CTO of RaCRx Fusion, Dr. Liu bridges rigorous academic discovery with the applied technology development needed to advance novel drug candidates from concept through preclinical validation — ensuring the platform's scientific foundation remains grounded in cutting-edge cancer biology.

Regulatory affairs executive with 18+ years guiding therapies from early development to global marketing approval and lifecycle management across small molecules, biologics, gene and cell therapies, and RNA therapeutics. Regulatory affairs employment and consulting history includes PTC Therapeutics, GSK, Sarepta Therapeutics, Affinia Therapeutics, and Vertex. As examples with Vertex, provided regulatory guidance for the sickle cell disease/transfusion-dependent beta-thalassemia CRISPR/Cas9-edited autologous one-time cellular gene therapy CASGEVY® and the Type 1 Diabetes cell therapies (VX-880 and VX-264).

Deep expertise in IND/IMPD preparation, CMC strategy, NDA/BLA/MAA submissions, accelerated approval pathways, and inspection readiness (BIMO, GMP, PLI/PAI). Proven success leading FDA, EMA, and PMDA interactions, including milestone meetings and complete response negotiations, to enable first-in-human through post-approval expansion.

Developed global regulatory strategies and executed Orphan Drug (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designations, de-risking and accelerating development timelines. Experienced in building and managing high-performing regulatory teams, aligning cross-functional clinical, quality, and manufacturing groups, and supporting commercialization for innovative therapies across oncology, neurology, metabolic, infectious, and rare diseases.